Antiangiogenic treatment as a pre-operative management of alveolar soft-part sarcoma

Pediatric Blood and Cancer

Volumn 57, Issue 6, 2011, Pages 1071-1073

  Conde, Nuria ^a   Cruz, Ofelia ^a   Albert, Asteria ^a   Mora, Jaume ^a  

^a HOSPITAL SANT JOAN DE DÉU   (Spain)

Author keywords

Alveolar soft part sarcoma; Antiangiogenic treatment; Bevacizumab; Vascular endothelial growth factor (VEGF)

Indexed keywords

BEVACIZUMAB; CELECOXIB; VASCULOTROPIN RECEPTOR 2;

ABSENCE OF SIDE EFFECTS; AIRWAY OBSTRUCTION; ALVEOLAR SOFT PART SARCOMA; ANTIANGIOGENIC THERAPY; ARTICLE; CASE REPORT; CERVICAL LYMPH NODE; CHILD; DYSPHAGIA; FEMALE; HUMAN; HUMAN TISSUE; JAW PAIN; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PREOPERATIVE TREATMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RARE DISEASE; RELIGION; TONGUE TUMOR; TUMOR BIOPSY; WEIGHT REDUCTION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD, PRESCHOOL; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PYRAZOLES; QUALITY OF LIFE; SARCOMA, ALVEOLAR SOFT PART; SULFONAMIDES; TONGUE NEOPLASMS; TREATMENT OUTCOME;

EID: 80052673381     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23241     Document Type: Article

References (13)

1. Flieder DB, Moran CA, Suster S, et al. Primary alveolar soft-part sarcoma of the mediastinum: A clinicopathological and immunohistochemical study of two cases. Histopathology 1997; 31: 469-473.
2. Bentley RP, Wake MJ, Raafat F, et al. Alveolar soft part sarcoma of the tongue. Br J Oral Maxillofac Surg 1999; 37: 451-454.
3. Ooi LP, Sim CS, Peck RH, et al. Alveolar soft part sarcoma of the tongue: A case report. Aust N Z J Surg 1993; 63: 240-242.
4. Wong C, Wellman TL, Lounsbury KM, et al. VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer. Gynecol Oncol 2003; 91: 513-517.
5. Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.
6. Jain RK. Antiangiogenic therapy for cancer: Current and emerging concepts. Oncology 2005; 19: 7-16.
7. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 3: 2335-2342.
8. Fanburg-Smith JC, Miettinen M, Folpe AL, et al. Lingual alveolar soft part sarcoma; 14 cases: Novel clinical and morphological observations. Histopathology 2004; 45: 526.
9. Kumar M, Patne S, et al. Lingual alveolar soft part sarcoma in a child managed successfully with surgery and chemotherapy. Indian J Cancer 2010; 47: 234-235.
10. Azizi AA, Haberler C, Czech T, et al. Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma. Lancet Oncol 2006; 7: 521-523.
11. Benesch M, Windelberg M, Sauseng W, et al. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol 2008; 19: 807-813.
12. Glade Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A Children's Oncology Group Study. J Clin Oncol 2008; 26: 399-405.
13. Virrey JJ, Liu Z, et al. Antiangiogenic activities of 2, 5-dimethyl-celecoxib on the tumor vasculature. Mol Cancer Ther 2010; 9: 631.